Kyverna Therapeutics (KYTX) provided a corporate update and outlined its strategic priorities for 2026. Highlights include: Advancing valuable commercial opportunity in stiff person syndrome following landmark registrational data; Biologics License Application submission anticipated in 1H 2026; First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis; Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial; Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company’s CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Announces $100 Million Public Offering
- Midday Fly By: Warner Bros. urges investors to reject Paramount bid
- Kyverna prices 13.3M shares at $7.50 in underwritten public offering
- Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts